1. Inflammatory
Bowel Disease (IBD)
Presented by:
M. Sufian
student of Nutrition Sciences(B/Sc)
Science & Research Branch of Islamic Azad University(SRBIAU)
All Rights Reserved by M Sufian
1/13/2012 1
m_sufian@behestandarou.com
2. Contents:
• Introduction
• Occurrence & Commonness
• Pathophysiology
• Diagnosis
Symptoms
Signs
• Complications
• Treatments
Medical
Surgical
• Q&A
• References
All Rights Reserved by M Sufian
1/13/2012 2
m_sufian@behestandarou.com
3. Introduction:
• IBD:Chronic inflammatory diseases of GI tract of
unknown etiology
• Commonly refers to
1) ulcerative colitis
Ulcerative colitis (UC) affects only the large intestine (*)
2) Crohn’s disease
Crohn’s disease (CD) can affect any part of the
gastrointestinal tract but most frequently attacks the distal
third of the small intestine & the colon
All Rights Reserved by M Sufian
1/13/2012 3
m_sufian@behestandarou.com
4. Introduction (continued)
• Diagnosed using clinical, endoscopic, and
histologic criteria
• No single finding is absolutely diagnostic for one
disease or the other
• Approx. 20% of patients have clinical picture that
falls between ulcerative colitis and Crohn’s
disease (indeterminate colitis)
• Many of the treatments available are effective
for both diseases
• Extraintestinal manifestations may be present in
both
All Rights Reserved by M Sufian
1/13/2012 4
m_sufian@behestandarou.com
5. Occurrence & Commoness
• Approx. 1 million people in U.S. have ulcerative
colitis (UC) or Crohn’s disease (CD)
• Most commonly observed in industrialized
nations; lowest in developing regions (also
higher rate in urban areas vs. rural areas)
• Incidence higher in Ashkenazi Jews
• Incidence is slightly higher in females than males
• Vast majority diagnosed between ages 15-40
All Rights Reserved by M Sufian
1/13/2012 5
m_sufian@behestandarou.com
6. Pathophysiology
• Still under investigation
• ? Defect in function of the intestinal immune
system (breakdown in defense barrier)
• Exposure of mucosa to microorganisms results in
inflammatory process causing
ulceration, bleeding and loss of fluids and
electrolytes
• ? Genetic predisposition (esp. when ileal disease
involved)
All Rights Reserved by M Sufian
1/13/2012 6
m_sufian@behestandarou.com
7. Pathophysiology(Cont’d)
All Rights Reserved by M Sufian
1/13/2012 7
m_sufian@behestandarou.com
8. Pathophysiology(Cont’d)
Pathophysiology in
Crohn's disease vs. ulcerative colitis
Crohn's disease Ulcerative colitis
Autoimmune Widely regarded as
disease an autoimmune No consensus
disease
Cyypkine Associated with Vaguely associated
response Th17 with Th2
All Rights Reserved by M Sufian
1/13/2012 8
m_sufian@behestandarou.com
9. Diagnostic:
Symptoms
Symptoms in Crohn's disease vs. ulcerative colitis
Crohn's disease Ulcerative colitis
Often porridge-like[6], Often mucus-like
Defecation
sometimes steatorrhea and with blood[6]
Tenesmus Less common[6] More common[6]
Fever Common[6] Indicates severe disease[6]
Fistulae Common[7] Seldom
Weight loss Often More seldom
All Rights Reserved by M Sufian
1/13/2012 9
m_sufian@behestandarou.com
10. Diagnostic:
Signs
Findings in diagnostic workup in Crohn's disease vs. ulcerative colitis
Sign Crohn's disease Ulcerative colitis
Terminal ileum involvement Commonly Seldom
Colon involvement Usually Always
Rectum involvement Seldom Usually[8]
Involvement around
Common[7] Seldom
the anus
No increase in rate of primary
Bile duct involvement Higher rate[9]
sclerosing cholangitis
All Rights Reserved by M Sufian
1/13/2012 10
m_sufian@behestandarou.com
11. Diagnostic:
Signs
Findings in diagnostic workup in Crohn's disease vs. ulcerative colitis
Sign Crohn's disease Ulcerative colitis
Patchy areas of inflammation Continuous area of
Distribution of Disease
(Skip lesions) inflammation[8]
Deep geographic and
Endoscopy Continuous ulcer
serpiginous (snake-like) ulcers
May be transmural, deep into
Depth of inflammation Shallow, mucosal
tissues[2][7]
Stenosis Common Seldom
May have non- necrotizing
Non-peri-intestinal crypt
Granulomas on biopsy non-peri- intestinal crypt
granulomas not seen[8]
granulomas[7][10][11]
All Rights Reserved by M Sufian
1/13/2012 11
m_sufian@behestandarou.com
12. Ulcerative colitis vs. Crohn’s
• Rectal bleeding common • Occasional rectal bleeding
• Abdominal pain uncommon • Abdominal pain common
• Rectal involvement almost 100% • Rectal involvement 50%
• Fistula formation rare • Fistula formation common
• Stricture & obstruction rare • Stricture and obstruction common
• Perirectal, perianal abscesses • Perirectal, perianal abscesses
uncommon common
• Continuous involvement • Discontinuous involvement
• Mucosa & submucosa involved • Transmural
• Small bowel not involved (*) • Small bowel often involved
• Risk of malignancy greatly • Risk of malignancy increased
increased
All Rights Reserved by M Sufian
1/13/2012 23
m_sufian@behestandarou.com
13. Treatment
Management in Crohn's disease vs. ulcerative colitis
Crohn’s disease Ulcerative colitis
Mesalazine less useful[12] More useful[12]
Antibiotics Effective in long-term[13] Generally not useful[14]
Often returns following Usually cured by
Surgery
removal of affected part removal of colon
All Rights Reserved by M Sufian
1/13/2012 45
m_sufian@behestandarou.com
14. Treatment (Medical)
1. Anti-inflammatory
agents(aminosalicylates,corticosteroids)
2. Immunosuppressant
3. Antibiotics
4. TNF (Tumor Necrosis Factor) inhibitors
5. Anti-diarrheal agents
6. Antispasmodic agents
7. Supportive therapy
** 75% of ulcerative colitis patients respond well to medical management
All Rights Reserved by M Sufian
1/13/2012 46
m_sufian@behestandarou.com
15. 1-Anti-inflammatories (aminosalicylates)
• Sulfasalazine (Azulfidine)-combination of sulfapyradine (anti-
bacterial) + 5-aminosalicylic acid (5-ASA)
– Greatest effect on IBD; mainstay of outpatient medical
treatment for mild-mod. active UC & CD
– Originally used to treat rheumatoid arthritis
– Possesses both anti-inflammatory & antibacterial properties
– Partially absorbed in jejunum but remainder passes to colon
– Therapeutic action of 5-ASA compounds: inhibition of
prostaglandin & leukotriene synthesis, free radical scavenging,
impairment of white cell adhesion and function, inhibition of
cytokine synthesis
– Watch for folate deficiency, abdominal discomfort & allergies to
sulfa compounds
All Rights Reserved by M Sufian
1/13/2012 47
m_sufian@behestandarou.com
16. 1-Anti-inflammatories (aminosalicylates)
• Mesalamine group- Asacol, Pentasa, Rowasa
– Coating 5-ASA with acrylic resins- permits drug delivery to distal
bowel & colon
– Effective for ileal & colon involvement
– Rapid absorption
– Enemas and suppositories
– Fewer side effects than sulfasalazine
– Olsalazine-delayed absorption;useful in colonic disease
All Rights Reserved by M Sufian
1/13/2012 48
m_sufian@behestandarou.com
17. 1-Anti-inflammatories (corticosteroids)
• Treatment of choice for acute attack IBD (including IV treatment;
enemas for acute proctitis)
• Generally used for moderate-severe IBD
• Not to be used for maintaining remission due to multiple & severe
side effects *
• Prednisone-synthetic glucocorticoid;powerful anti-inflammatory
action
– Usually tapered doses
– IV use- methylprednisolone, dexamethasone
• Budesonide (Entocort EC)- newer type
– Synthetic steroid coated with ethylmethylcellulose which delays its
release until ileum & descending colon
• **Side effects often outweigh benefits if used for prolonged
period of time
All Rights Reserved by M Sufian
1/13/2012 49
m_sufian@behestandarou.com
18. 2-Immunosuppressants
• Reduce inflammation by suppressing immune system’s
response (which might damage digestive tissue) to
invading virus or bacterium
• Azathioprine (Imuran) & mercaptopurine (6-MP,
Purinethol)
– help reduce signs and sx of IBD and heal fistulas from CD
– inhibits mitosis
– Increases risk of neoplasia
– Serious hepatic, renal, & hematological side effects
All Rights Reserved by M Sufian
1/13/2012 50
m_sufian@behestandarou.com
19. 2-Immunosuppressants
• Methotrexate (Rheumatrex)- used for patients
who do not respond to other medications
• Cyclosporine (Neoral, Sandimmune)-
administered IV for CD with fistulas
All Rights Reserved by M Sufian
1/13/2012 51
m_sufian@behestandarou.com
20. 3-Antibiotics
• IBD is associated with frequent bacterial
infections especially with toxic
megacolon, fistulas and fulminant disease
• Most effective antibiotics: metronidazole
(Flagyl), ampicillin, cephalosporins, amonioglyco
sides, ciprofloxacin (Cipro)
All Rights Reserved by M Sufian
1/13/2012 52
m_sufian@behestandarou.com
21. 4-TNF (tumor necrosis factor) inhibitors
• TNF is a protein produced by immune system;
chemical messenger that can cause
inflammation & tissue damage
• Etanercept (Enbrel) – TNF receptor blocker;
binds to alpha & beta TNF
– Used to treat RA; not yet FDA approved for treating
Crohn’s
All Rights Reserved by M Sufian
1/13/2012 53
m_sufian@behestandarou.com
22. 4-TNF Inhibitors
• Infliximab (Remicade)- neutralizes cytokine TNF
alpha
– Increased risk infections (reactivation of TB or
granulomatous disease)
– Usually for moderate-severe disease
– May be used for long-term therapy
All Rights Reserved by M Sufian
1/13/2012 54
m_sufian@behestandarou.com
23. 5-Antidiarrheal agents
• Decrease peristalsis & therefore intestinal
motility
• Improves diarrhea& prevents loss of fluid &
electrolytes
• Loperamide (Imodium), Atropine (Lomotil)
• Cholestyramine (Questran)- inhibits
enterohepatic reuptake of bile salts
All Rights Reserved by M Sufian
1/13/2012 55
m_sufian@behestandarou.com
24. 5-Antispasmodic agents
• Treat functional disturbances of GI motility
• Dicyclomine (Bentyl)- anticholinergic; blocks
action of acetylcholine at parasympathetic sites
in secretory glands, smooth muscle & CNS
All Rights Reserved by M Sufian
1/13/2012 56
m_sufian@behestandarou.com
25. 6-Supportive therapy
• (In addition to adequate nutritional support)
– Vitamin B12
– Iron
– Folic acid
All Rights Reserved by M Sufian
1/13/2012 57
m_sufian@behestandarou.com
26. Surgical Treatment
• **Surgical removal of large bowel (colectomy)
will result in cure for ulcerative colitis
• Not the case for Crohn’s; surgical removal of the
affected bowel segment in CD will not prevent
the later appearance of disease at an adjacent or
distant site
All Rights Reserved by M Sufian
1/13/2012 58
m_sufian@behestandarou.com
27. Surgical Treatment (Ulcerative Colitis)
• Main indications: failure of medical treatment,
complications (toxic megacolon, perforation) and
risk of malignancy
• Resection of colon & rectum
(panproctocolectomy) is curative
– Fecal diversion via ileostomy or ileo-anal anastomosis
in form of ileal pouch
• Pouch may cause mechanical problems (40% develop
inflammation resembling UC, 15% may need further surgery)
All Rights Reserved by M Sufian
1/13/2012 59
m_sufian@behestandarou.com
28. Surgical Treatment (Ulcerative Colitis)
• 10% will have colectomy during 1st year of dx
– 4% will have surgery during 2nd year
– 1 % annually in subsequent years
– Extent of colitis at diagnosis affects need for
subsequent surgery (colectomy rate for patients with
pancolitis is 32%)
All Rights Reserved by M Sufian
1/13/2012 60
m_sufian@behestandarou.com
29. Surgical Treatment (Crohn’s Disease)
• Limited to dealing with complications such as
stricture formation, perforation and fistulae
• 30% need surgery within 1st year
• For the remainder, surgery rate is 5% per year
• Following resection, 30% will require further
surgery within 5 years, & 50% within 10 years
• Complications are frequent; least invasive
procedures desirable
All Rights Reserved by M Sufian
1/13/2012 61
m_sufian@behestandarou.com
30. Underwriting IBD: Mild Ulcerative Colitis
Distal or rectal involvement only
• 5 or fewer stools/day
• Tx with retention enemas or oral anti-
inflammatory meds
• No systemic or extracolonic manifestations
All Rights Reserved by M Sufian
1/13/2012 62
m_sufian@behestandarou.com
31. Moderate Ulcerative Colitis
• No currently active pancolitis
• No serious complications
• No worse than mild anemia
• Treatment may require intermittent use of oral
steroids or other cytotoxic drugs
All Rights Reserved by M Sufian
1/13/2012 63
m_sufian@behestandarou.com
32. Severe Ulcerative Colitis
• Active pancolitis with frequent
diarrhea, abdominal pain
• Severe & typical systemic findings
• Weight loss > 10% of body weight
• Lab results reveal moderate-severe anemia
and/or hypoalbuminemia
• Recent (w/in 5 yrs) toxic megacolon or multiple
surgeries
• Treatment requires high doses of steroids or
multiple cytotoxic medications
All Rights Reserved by M Sufian
1/13/2012 64
m_sufian@behestandarou.com
33. Other considerations (UC)
• Cirrhosis or sclerosing cholangitis (documented
or suspected)
• Alkaline phosphatase or LFT elevations w/out
liver biopsy or work-up
• Fatty liver or pericholangitis confirmed by liver
biopsy + significant LFT elevations
• (Postpone?) Recent diagnosis
• (Postpone?) 0-6 months following surgery
All Rights Reserved by M Sufian
1/13/2012 65
m_sufian@behestandarou.com
34. Underwriting IBD (Mild Crohn’s Disease)
• Use of anti-diarrheal meds, no antibiotic or
immunosuppressive therapy
• Near normal bowel habits
• Infrequent attacks
• No anemia, normal sed rate
All Rights Reserved by M Sufian
1/13/2012 66
m_sufian@behestandarou.com
35. Moderate Crohn’s Disease
• Medications needed to control symptoms (ie,
Flagyl, Asacol, Azulfidine)
• Limited disease
• No more than 2 surgeries
• Sed rate up to 2x normal
All Rights Reserved by M Sufian
1/13/2012 67
m_sufian@behestandarou.com
36. Severe Crohn’s Disease
• Multiple (3 or more) surgeries
• Multiple medications including oral
steroids, immunosuppressants, TNF inhibitors
• Extensive disease
• Anemia, elevated sed rate
• Weight loss (> 10% body weight)
All Rights Reserved by M Sufian
1/13/2012 68
m_sufian@behestandarou.com
37. Crohn’s Disease- Favorable factors
• Normal CBC
• Ileal involvement only
• Stable weight
• Non-steroidal meds only
• Colonoscopies every 12-24 months
• Older age
All Rights Reserved by M Sufian
1/13/2012 69
m_sufian@behestandarou.com
38. Crohn’s Disease- Unfavorable Factors
• Low blood counts on CBC
• Multiple sites in GI tract
• Low and/or fluctuating weight
• Steroid use
• Surgical intervention (multiple)
• Poor follow-up/compliance
All Rights Reserved by M Sufian
1/13/2012 70
m_sufian@behestandarou.com
39. Crohn’s Disease – other consideratons
• Cirrhosis or sclerosing cholangitis (documented or
suspected)
• Alkaline phosphatase or LFT elevations w/out liver biopsy
or work-up
• Fatty liver or pericholangitis confirmed by liver biopsy +
significant LFT elevations
• Consider postponing if recent diagnosis (0-1 year since
dx)
• (Postpone?) If CD diagnosed > 10 yrs ago (w/colonic
involvement) and there is no recent colonoscopy
• (Postpone?) Colonoscopy/biopsy shows any degree of
dysplasia
All Rights Reserved by M Sufian
1/13/2012 71
m_sufian@behestandarou.com
40. Questions?
All Rights Reserved by M Sufian
1/13/2012 72
m_sufian@behestandarou.com
41. References
1. ^ Baumgart DC, Carding SR (2007). "Inflammatory bowel disease: cause and immunobiology.". The Lancet 369 (9573): 1627–40.
doi:10.1016/S0140-6736(07)60750-8. PMID 17499605.
2. ^ a b Baumgart DC, Sandborn WJ (2007). "Inflammatory bowel disease: clinical aspects and established and evolving therapies.".
The Lancet 369 (9573): 1641–57. doi:10.1016/S0140-6736(07)60751-X. PMID 17499606.
3. ^ Xavier RJ, Podolsky DK (2007). "Unravelling the pathogenesis of inflammatory bowel disease.". Nature 448 (7152): 427–34.
doi:10.1038/nature06005. PMID 17653185.
4. ^ "Crohn's & Colitis Foundation of America".
5. ^ Elson, CO; Cong, Y; Weaver, CT; Schoeb, TR; Mcclanahan, TK; Fick, RB; Kastelein, RA (2007). "Monoclonal Anti–Interleukin 23
Reverses Active Colitis in a T Cell–Mediated Model in Mice". Gastroenterology 132 (7): 2359. doi:10.1053/j.gastro.2007.03.104.
PMID 17570211.
6. ^ a b c d e f internetmedicin.se > Inflammatorisk tarmsjukdom, kronisk, IBD By Robert Löfberg. Retrieved Oct 2010 Translate.
7. ^ a b c d Hanauer, Stephen B.; William Sandborn (2001-03-01). "Management of Crohn's disease in adults" (PDF). American Journal
of Gastroenterology 96 (3): 635–43. doi:10.1111/j.1572-0241.2001.03671.x. PMID 11280528. Retrieved 2009-11-07.
8. ^ a b c Kornbluth, Asher; David B. Sachar (July 2004). "Ulcerative colitis practice guidelines in adults (update): American College of
Gastroenterology, Practice Parameters Committee" (PDF). American Journal of Gastroenterology 99 (7): 1371–85.
doi:10.1111/j.1572-0241.2004.40036.x. PMID 15233681. Archived from the original on April 6, 2008. Retrieved 2009-11-07.
9. ^ Broomé, Ulrika; Annika Bergquist (February 2006). "Primary sclerosing cholangitis, inflammatory bowel disease, and colon
cancer". Seminars in Liver Disease 26 (1): 31–41. doi:10.1055/s-2006-933561. PMID 16496231.
10. ^ Shepherd, NA. (August 2002). "Granulomas in the diagnosis of intestinal Crohn's disease: a myth exploded?". Histopathology 41
(2): 166–8. doi:10.1046/j.1365-2559.2002.01441.x. PMID 12147095.
11. ^ Mahadeva, U.; Martin, JP.; Patel, NK.; Price, AB. (July 2002). "Granulomatous ulcerative colitis: a re-appraisal of the mucosal
granuloma in the distinction of Crohn's disease from ulcerative colitis.". Histopathology 41 (1): 50–5. doi:10.1046/j.1365-
2559.2002.01416.x. PMID 12121237.
12. ^ a b c Pages 152-156 (Section: Inflammatory bowel disease(IBD)) in:Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to
Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.
All Rights Reserved by M Sufian
1/13/2012 73
m_sufian@behestandarou.com
Notas del editor
PATHOGENESIS OF IBDAlthough genetic susceptibility, luminal antigenic drive, and environmental triggers are each important, animal models demonstrate that no single factor is sufficient to induce chronic relapsing, immune-mediated intestinal inflammation. Chronic inflammatory bowel diseases depend on the interaction of these essential components, each of which is necessary but not sufficient to induce disease.
1-The main difference between Crohn's disease and UC is the location and nature of the inflammatory changes. Crohn's can affect any part of the gastrointestinal tract, from mouth to anus (skip lesions), although a majority of the cases start in the terminal ileum. Ulcerative colitis, in contrast, is restricted to the colon and the rectum.Crohn's & Colitis Foundation of America".2-Microscopically, ulcerative colitis is restricted to the mucosa (epithelial lining of the gut), while Crohn's disease affects the whole bowel wall ("transmural lesions").3-Finally, Crohn's disease and ulcerative colitis present with extra-intestinal manifestations (such as liver problems, arthritis, skin manifestations and eye problems) in different proportions.
Optimal treatment of inflammatory bowel disease depends on what form it consists of. For example, mesalazine is more useful in ulcerative colitis than in Crohn's disease.[12] Generally, depending on the level of severity, IBD may require immunosuppression to control the symptom, such as prednisone, TNF inhibition, azathioprine (Imuran), methotrexate, or 6-mercaptopurine. More commonly, treatment of IBD requires a form of mesalazine.
Often, steroids are used to control disease flares and were once acceptable as a maintenance drug. In use for several years in Crohn's disease patients and recently in patients with ulcerative colitis, biologicals have been used such as TNF inhibitors. Severe cases may require surgery, such as bowel resection, strictureplasty or a temporary or permanent colostomy or ileostomy. Alternative medicine treatments for bowel disease exist in various forms, however such methods concentrate on controlling underlying pathology in order to avoid prolonged steroidal exposure or surgical excisement.[15]